Farmak pharmaceutical company to invest EUR 30 mln in building innovative R&D center in Kyiv
Farmak pharmaceutical company (Kyiv) is investing EUR 30 million in the construction of an innovative research R&D center in Kyiv.
According to a press release from the company, the center is to open in 2023.
According to Executive Director of Farmak Volodymyr Kostiuk, the decision to build an R&D center was made a few years ago due to the expansion of the geography of presence and the portfolio of medicines.
In the new center, in particular, analytical laboratories will be concentrated, they will have about a hundred liquid and gas chromatographs and a number of modern devices for the development and testing of drugs.
In addition, the R&D center will house a technological laboratory with equipment for the development of finished drugs with various methods of their delivery to the human body and the implementation of personalized medicine protocols of the 21st century.
In the new R&D center, it is planned to continue working in three main areas: finished dosage forms, proprietary active pharmaceutical ingredients, as well as an innovative area in which Farmak has been working since 2015 - biotechnological active pharmaceutical ingredients. All processes will be digitized.
In addition, on the basis of the new complex, a special location will be equipped for young scientists who are not employees of the company, where they can engage in scientific activities and create prototypes of drugs.
The concept design of the complex was developed by Makhno Studio.
Farmak is the leader of the Ukrainian pharmaceutical market. The company's product portfolio includes about 200 brands. Among the main directions are endocrinological, gastroenterological, cardiological, neurological, anti-cold and other drugs.